Streetwise Reports' Article Archives — August 2019 back to current month (26)
Shares of Lannett Co. are up 40% today after announcing that it secured rights to be the exclusive U.S. distributor of Sinotherapeutics' antifungal drug that is an AB-rated generic for Noxafil.
The drug's features and its developer's commercial plans are discussed in an H.C. Wainwright & Co. report.
Details from this clinical program are discussed, along with Q2/19 earnings and the next stock catalyst, in an H.C. Wainwright & Co. report.
An update on the Canadian company, including its Q2/19 results and its next expected catalyst, is provided in a Haywood report.
Demand for the Canadian company's product is growing in the Asia-Pacific region.
Why Provention Bio Is in My Portfolio (08/23/2019)
Orphan drug and breakthrough therapy status, which could mean this company's lead candidate is on the FDA fast track, translates to huge opportunities for both those suffering from diabetes and investors, says Daniel Carlson of Tailwinds Research.
Shares of Retrophin fell to a 52-week low on the news that topline results from its fosmetpantotenate Phase 3 FORT Study for PKNA treatment failed to meet expectations.
The initiative, to start in Calgary, is expected to expand rapidly into other cities.
The country represents a significant market for feed consumption.
The next steps for each of the programs are outlined in a Dawson James Securities report.
Dublin-based Medtronic reported Q1/20 earnings and revised its full-year earnings outlook upward sending shares up more than 5% today.
A Potential CBD Processor with 'Blue-Sky Prospects' (08/20/2019)
Peter Epstein of Epstein Research speaks with Martin Doane, CEO of Leviathan Cannabis Group, about the company's international plans to grow hemp and produce a hemp-derived CBD isolate and what sets the company apart from its peers.
Solid Biosciences' shares are up by more than 40% today after Chardan Capital Markets upgraded the firm's shares from "neutral" to "buy" and raised its price target from $7.50 to $10.00/share.
InMode Ltd. reported Q2/19 earnings and announced that international pop superstar Paula Abdul will be its brand ambassador sending shares "Straight Up" 15% as investors "Rush Rush" to purchase shares today.
Deciphera Pharmaceuticals announced positive top-line results from the INVICTUS pivotal phase 3 clinical study of ripretinib in patients with advanced gastrointestinal stromal tumors.
The latest development concerning this clinical asset and other Q2/19 highlights are provided in an H.C. Wainwright & Co. report.
Amgen shares are trading 5–6% higher today on news that the company has won its Enbrel (etanercept) patent court case.
Shares in Puma Biotechnology are trading 20% higher today after the company released Q2/19 earnings and reported positive NERLYNX revenue growth.
Avedro Shares Looking Up 35% with Glaukos Merger (08/08/2019)
Avedro Inc. and Glaukos Corp. announced that the firms' boards of directors have executed a definitive merger agreement. The all-stock deal is expected to close in Q4/19.
Guardant Health Reports Quarterly Revenue Up 178% (08/07/2019)
Guardant Health Inc. reported strong growth for Q2/19 versus the same period last year and raised its full-year 2019 revenue guidance to $180–190 million.
Allakos Inc. shares are soaring today as the company reported Q2/19 earnings and announced positive results from its phase 2 study for its AK002 inhibitor used in the treatment of eosinophil and mast cell related diseases.
The company's latest science, presented at a recent conference, is discussed in a ROTH Capital Partners report.
Biotech's Mosquito Test 'Gains Market Acceptance' (08/02/2019)
This West Nile virus test and others including cancer diagnostic tests in the Utah company's pipeline are discussed in an H.C. Wainwright & Co. report.
Tandem Diabetes Care's second quarter earnings highlighted a 290% increase in unit sales of its t:slim X2 insulin pumps that feature integrated continuous glucose monitoring and remote software update capability.
Gaia Grow Corp. CEO Frederick Pels speaks with Peter Epstein of Epstein Research on the day his company begins trading on the TSX Venture Exchange.
Shares of Vanda Pharmaceuticals traded nearly 30% higher after the company released Q2/19 earnings and positive sales trends for both HETLIOZ and Fanapt.
|"From a stock perspective, 2019 was a clear breakout year for DRRX."|